Beone Medicines LTD.
Forward trial catalysts linked to ONC
CSA tracks 1 forward catalyst for Beone Medicines LTD. across 1 asset, spanning Phase 3. The nearest is a readout expected Dec 31, 2026 (day precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, B-cell Malignancies, and 3 more.
ONC in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Beone Medicines LTD. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
9 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| zanubrutinib | NCT03336333 | Phase 3 | Active, not recruiting | 2021-05-07 | Experimental | BeiGene | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
| zanubrutinib | NCT04002297 | Phase 3 | Active, not recruiting | 2026-04-27 | Experimental | BeOne Medicines | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma |
| zanubrutinib | NCT04170283 catalyst | Phase 3 | Active, not recruiting | 2026-12-31 | Experimental | BeOne Medicines | B-cell Malignancies |
| zanubrutinib | NCT04662255 | Phase 3 | Active, not recruiting | 2027-11 | Active comparator | Loxo Oncology, Inc. | Lymphoma, Mantle-Cell |
| zanubrutinib | NCT05100862 | Phase 3 | Active, not recruiting | 2028-07 | Experimental | BeOne Medicines | Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma |
| zanubrutinib | NCT06742996 | Phase 3 | Recruiting | 2028-08-31 | Experimental | BeOne Medicines | Mantle Cell Lymphoma; B Cell Lymphoma |
| zanubrutinib | NCT07277231 | Phase 3 | Recruiting | 2031-02 | Experimental | BeOne Medicines | Chronic Lymphocytic Leukemia |
| zanubrutinib | NCT07377578 | Phase 3 | Recruiting | 2031-05-30 | Active comparator | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma |
| zanubrutinib | NCT06073821 | Phase 3 | Active, not recruiting | 2032-02 | Experimental | BeOne Medicines | CLL |
Every trial the CSA sample links to ONC's tracked assets, including trials another sponsor runs and trials where the asset is not the experimental arm.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →